Literature DB >> 17334736

[Glucocorticoid induced osteoporosis].

U Lange1, U Müller-Ladner.   

Abstract

Secondary osteoporosis is caused by various non-physiological factors. It affects 5% of all patients with osteoporosis and accounts for 20% of all osteoporotic fractures. Glucocorticoid induced osteoporosis is the most common form of secondary osteoporosis, whereas an endogenous Cushing syndrome rarely results in decreased bone mineral density. In addition, chronic inflammatory diseases which require a glucocorticoid therapy also need to be considered in the context of osteoporosis. This article presents the current data on glucocorticoid induced osteoporosis and an update of the proposed DVO (Dachverbandes Osteologie, umbrella organization of German scientific osteology-related societies) guidelines 2006.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17334736     DOI: 10.1007/s00393-007-0151-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  16 in total

Review 1.  Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence.

Authors:  Mishaela R Rubin; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2002-09       Impact factor: 5.958

2.  Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark.

Authors:  P Vestergaard; M L Olsen; S Paaske Johnsen; L Rejnmark; H Toft Sørensen; L Mosekilde
Journal:  J Intern Med       Date:  2003-11       Impact factor: 8.989

3.  Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice.

Authors:  Daniel H Solomon; Jeffrey N Katz; Jonathan P Jacobs; Alison M La Tourette; Jonathan Coblyn
Journal:  Arthritis Rheum       Date:  2002-12

4.  Oral corticosteroids and fracture risk: relationship to daily and cumulative doses.

Authors:  T P van Staa; H G Leufkens; L Abenhaim; B Zhang; C Cooper
Journal:  Rheumatology (Oxford)       Date:  2000-12       Impact factor: 7.580

Review 5.  The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.

Authors:  T P van Staa; H G M Leufkens; C Cooper
Journal:  Osteoporos Int       Date:  2002-10       Impact factor: 4.507

Review 6.  Use of oral corticosteroids and risk of fractures.

Authors:  T P Van Staa; H G Leufkens; L Abenhaim; B Zhang; C Cooper
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

7.  Adherence with osteoporosis practice guidelines: a multilevel analysis of patient, physician, and practice setting characteristics.

Authors:  Daniel H Solomon; M Alan Brookhart; Tejal K Gandhi; Andrew Karson; Soheyla Gharib; E John Orav; Shimon Shaykevich; Andrea Licari; Danielle Cabral; David W Bates
Journal:  Am J Med       Date:  2004-12-15       Impact factor: 4.965

8.  [Drug therapy in postmenopausal osteoporosis. An analysis of healty service delivery].

Authors:  Kurt Bestehorn; Angela Zink; Reiner Dreher
Journal:  Z Arztl Fortbild Qualitatssich       Date:  2002-12

9.  Low-dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures?

Authors:  A A van Everdingen; D R Siewertsz van Reesema; J W G Jacobs; J W J Bijlsma
Journal:  Clin Exp Rheumatol       Date:  2003 Mar-Apr       Impact factor: 4.473

10.  Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study.

Authors:  Bruno Frediani; Paolo Falsetti; Stefania Bisogno; Fabio Baldi; Caterina Acciai; Georgios Filippou; Maria Romana Bacarelli; Paolo Filipponi; Mauro Galeazzi; Roberto Marcolongo
Journal:  J Rheumatol       Date:  2004-06       Impact factor: 4.666

View more
  2 in total

1.  [Managing comorbidities of inflammatory rheumatic diseases].

Authors:  K de Groot; E Märker-Hermann
Journal:  Internist (Berl)       Date:  2011-06       Impact factor: 0.743

2.  The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis.

Authors:  Peter Oelzner; Sybille Franke; Gabriele Lehmann; Thorsten Eidner; Gert Hein; Gunter Wolf
Journal:  Rheumatol Int       Date:  2010-09-07       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.